Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile

Antimicrob Agents Chemother. 2007 May;51(5):1840-3. doi: 10.1128/AAC.01283-06. Epub 2007 Feb 16.

Abstract

In silico, we identified fusA (2,067 bp) in Clostridium difficile 630. Sequencing of fusA in posttherapy fusidic acid-resistant C. difficile isolates from 12 patients with C. difficile-associated diarrhea (CDAD) identified fusA mutations, one or two nonsynonymous substitutions, or in one case a deletion of one codon associated with resistance. Five of these mutations have previously been described in fusA of fusidic acid-resistant Staphylococcus aureus, but seven were novel fusA mutations. Fusidic acid monotherapy for CDAD seemed to rapidly select conserved resistant mutants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Clostridioides difficile / drug effects*
  • Clostridioides difficile / genetics
  • Clostridioides difficile / growth & development
  • Diarrhea / drug therapy
  • Fusidic Acid / pharmacology*
  • Fusidic Acid / therapeutic use
  • Humans
  • Microbial Sensitivity Tests
  • Mutation*
  • Peptide Elongation Factor G / genetics*

Substances

  • Anti-Bacterial Agents
  • Peptide Elongation Factor G
  • Fusidic Acid